Abstract: Disclosed are a method of preparing a saccharide that contains a 3-fluoro-sialic acid and a method of bonding it to a homogeneous antibody. Also within the scope of this invention are compounds each containing a 3-fluoro-sialic acid, monoclonal antibodies bonded to ?2,6-linked 3-fluoro-sialo-side terminated N-glycans, and treatment of cancer with such monoclonal antibodies.

Abstract: The present invention relates to a system and method for predicting blood glucose levels in a non-invasive manner using deduction learning. The deduction learning (DL) model 10 of the present invention predicts blood glucose level 300 based on the relationship or correlation between blood glucose level variation and PPG signal variation. Specifically, the DL model 10 of the present invention comprises a differential cell 100 (DC) configured to calculate predicted blood glucose level BGpred 300 using two PPG signals Si 200b and Si?1 200a, a BG i?1,ref 230 and relationship or correlation between variances of the two PPG signals and variances of the reference blood glucose level 230 and the predicted blood glucose level 300.

Abstract: A system and method for image-guided microscopic illumination are provided. A processing module controls an imaging assembly such that a camera acquires an image or images of a sample in multiple fields of view, and the image or images are automatically transmitted to a processing module and processed by the first processing module automatically in real-time based on a predefined criterion so as to determine coordinate information of an interested region in each field of view. The processing module also controls an illuminating assembly to illuminate the interested region of the sample according to the received coordinate information regarding to the interested region, with the illumination patterns changing among the fields of view.

Abstract: The present invention relates to biomarkers, methods and assay kits for predicting prognosis and/or monitoring progression of prostate cancer. The biomarkers include a glycosyltransferases [core 1 beta-3-galactosyltransferase (C1GALT1) and/or ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3GAL1)] gene product, its saccharide substrate/product, and/or a galectin-4 gene product.

Abstract: The present invention relates to a method for removing undifferentiated embryonic stem cells. In particular, the present invention relates to a method for removing undifferentiated embryonic stem cells by using cardiac glycosides (CGs). The present invention also relates to a method for preparing differentiated cells in which undifferentiated embryonic stem cells have been removed and a method for cell therapy by using such differentiated cells.

Abstract: Disclosed is a modified carbonaceous material, which includes hexagonal carbon networks in a layered stacking structure and acidic functional groups bonded to the hexagonal carbon networks and mainly existing at edges of the layered carbonaceous structure. Accordingly, the close proximity of acid moiety at the edges can resemble the center of hydrolysis enzymes, resulting in enhancement of hydrolytic efficiency. Additionally, the acid-functionalized carbonaceous material can also be applied in the capture and storage of carbon dioxide due to its unexpectedly higher capacity for CO2 molecular.

Abstract: A system for use in a poultry house includes a control server, a network gateway disposed in the poultry house and equipping with a wireless communication capability; a movable sensor module disposed in the poultry house, wherein the movable sensor module is movable within the poultry house for obtaining a plurality of environmental parameters associated with specific locations within the poultry house, and a sampling machine disposed in the poultry house for obtaining a sample of poultry waste on the ground of the poultry house. The movable sensor module transmits the environmental parameters to the network gateway, and the network gateway transmits the environmental parameters to the control server for processing the environmental parameters.

Abstract: The present invention relates to combined therapy of cancer using an epithelial cell adhesion molecule (EpCAM) inhibitor and a Wnt signaling inhibitor. Specifically, the EpCAM inhibitor is an antibody which is directed to an extracellular domain (EpEX) of EpCAM. The combined therapy is effective in inducing apoptosis of cancer cells, inhibiting cancer sternness properties, tumor progression and/or metastasis, and/or prolonging survival of a cancer patient.

Abstract: The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.

Abstract: Disclosed herein are method and/or kit for rendering a diagnosis on whether a subject is suffering from peripheral neuropathy pain. The method comprises detecting the presence of advillin in a biological sample by forming an immune complex between advillin and a monoclonal antibody specifically binds thereto. Also disclosed herein is a method of treating a subject suffering from peripheral neuropathy pain.

Abstract: Provided herein are compounds of Formula (I). The compounds described herein are useful in treating a disease associated with the expression of endogenous embryonic/fetal globin (e.g., ? globin) in erythrocytes (e.g., treating ?-thalassemia and/or sickle cell disease through at least the induction of the globin gene expression in erythrocytes), and/or anemia (?-thalassemia and/or sickle cell anemia). The compounds described herein are useful in treating, delaying, and/or preventing the adverse effects of ?-thalassemia and/or sickle cell disease, inducing ? globin production, and/or inducing the expression of embryonic/fetal globin genes in a subject, cell, tissue, or biological sample. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for inducing ? globin production described herein and for treating any of the target diseases described herein.

Abstract: An isolated nucleic acid encoding a C-terminal fragment of paraspeckle component 1 (PSPC1) is disclosed. The C-terminal fragment of the PSPC1 comprises an extension of more than 10 but no greater than 131 amino acid residues with its C-terminal amino acid identical to the C-terminus of the PSPC1 sequence SEQ ID NO: 3 and exhibits a biological activity against tumor cells. The tumor cells are associated with either PSPC1 or protein tyrosine kinase 6 (PTK6), or both. The anti-tumor activity is at least one selected from the group consisting of: (a) suppressing tumor cell growth; (b) suppressing tumor cell progression; (c) suppressing tumor cell metastasis; (d) decreasing PSPC1 expression; and (e) decreasing oncogenic PTK6 expression in cytoplasm. Also disclosed is a peptide comprising a C-terminal fragment sequence of PSPC1. A reagent kit and method for predicting tumor progression, metastasis, and prognosis in a cancer patient are also disclosed.

Abstract: A transgenic rice plant containing in its genome a recombinant DNA construct that includes a first nucleic acid having a sequence of a first Golden 2-like transcription factor (GLK) gene operably linked to its natural promoter and 5? untranslated region (5?UTR), and a second nucleic acid having a sequence of a second GLK gene operably linked to its natural promoter and 5?UTR, the second GLK gene being distinct from the first GLK gene. The first GLK gene and the second GLK gene are both from a C4 plant and the transgenic rice plant exhibits a 65-106% increase in shoot biomass and a 50-95% increase in grain yield, as compared to an untransformed wild-type rice plant. Also provided is a method for producing the transgenic rice plant and a recombinant DNA construct that can be used in the method.

Abstract: Methods of preparing cell cultures (e.g. tumor spheroids), methods of evaluating a therapeutic agent for cancer, and methods of cancer treatment.

Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

Abstract: The present invention provides novel pharmaceutical formulations comprising derivatives of NDGA, including M4N (tetra-0-methyl nordihydroguaiaretic acid) and temozolomide and their use in the inhibition and treatment of neoplastic diseases, including glioblastoma multiforme, lung and other cancers.

Abstract: The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.

Abstract: The present invention pertains to methods of coating antimicrobial peptides on the biomaterial and the biomaterial coated thereby. The coating solution described herein comprises one or more antimicrobial peptides (AMPs) dissolved in a buffer containing an anionic surfactant, wherein the AMPs are amphipathic and cationic.

Abstract: The present disclosure relates to mir-17˜92 as a candidate therapeutic or diagnostic target of motor neuron (MN) degeneration diseases. Expression of mir-17˜92 is sustained throughout adulthood in spinal MNs and specifically decreases before the onset of MN loss in SOD1G93A mice. Accordingly, mir-17˜92 can be used as a candidate therapeutic target for ALS.

Abstract: Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N6-(4-hydroxybenzyl)adenosine and analogous compounds with amino acids or peptides. In one embodiment of the invention, the compound is 5?-glycylcarbonyl-N6-(4-hydroxybenzyl)adenosine (I-a1). In another embodiment of the invention, the compound is 5?-deoxy-5?-(N?-glycylureido)-N6-(4-hydroxybenzyl)adenosine (I-d1). Also disclosed are methods of making and using the same.